Assessment of prognostic factors in epithelial ovarian cancer

Abstract

O varian cancers constitute 4% of female cancers. Ovarian cancer is the second most common gynecological cancer.[1] About 95% of the ovarian malignancies are epithelial tumors. Serous ovarian cancer is the most common epithelial ovarian cancers. Its treatment modalities include surgery, adjuvant chemotherapy, and supportive therapy. It has a rather poor course of prognosis. 5-year survival rate of ovarian cancer is about 40-45%. This ratio ranges from 15% to 95% based on various factors affecting prognosis. [2][3][4][5][6][7] There are numerous clinical, pathological and biological prognostic factors. Clinical factors affecting prognosis include age, performance status, menarche age, menopausal status, and parity; pathologic factors include stage, pathologic grade, cytologic findings, the presence of ascites and residual disease after surgery and biological factors comprise various gene expressions. Furthermore, the cheObjectives: Ovarian cancer is the second most common gynecological cancer, and has a 5-year survival rate of about 40% to 45%. This ratio ranges from 15% to 95%, based on prognostic factors. There are numerous clinical, pathological and biological factors related to prognosis. The aim of this study was to assess prognostic factors in advanced epithelial ovarian cancer. Methods: A total of 119 stage III and stage IV ovarian cancer patients were evaluated. The patient's age, menopausal status, age of menarche, number of children, height and weight values, surgery, tumor histopathological features, presence of metastasis, residual tumor volume, presence of ascites, abdominal lavage cytology, chemotherapy regimen, number of chemotherapy cycles, the first and last chemotherapy dates, relapse, and recent status were evaluated. Results: The median age of the study patients was 54 years (minimum: 34, maximum: 79 years). The pathological stages were 10 (8.6%) patients with IIIA, 6 (5%) patients with IIIB, 76 (63.9%) patients with IIIC, and 27 (22.7%) patients with stage IV. In multivariate analysis, age of diagnosis (hazard ratio [HR]: 0.44; 95% confidence interval [CI], 0.22-087; p=0.01), postoperative tumor residual status (HR: 0.32; 95% CI, 0.14-0.71; p<0.01), number of adjuvant chemotherapies (HR: 0.48; 95% CI, p=0.04), and platinum sensitivity (HR: 0.37; 95% CI, 0.18-0.74; p<0.01) were found to be independent variables related to longer survival. Notably, a patient treated with more than 6 cycles of chemotherapy had a worse prognosis. Conclusion: Independent indicators of a poor prognosis in our study were determined to be advanced age at diagnosis, a residual tumor more than 2 cm in size, more than 6 cycles of chemotherapy, and the presence of platinumresistant disease. A multidisciplinary approach is needed to improve prognosis.

Aging affects regrowth of stealth peritoneal dissemination of advanced ovarian cancer: A multicenter retrospective cohort study

“…This result is consistent with previous reports analyzing prognosis of elderly patients with advanced OvCa 5,20 . There are some studies that linked aging and tumor progression.…”

CD133, CD44, and ALDH1A1 as cancer stem cell markers and prognostic factors in epithelial ovarian cancer

“…Onal et al 11 found that patients with metastasis at the time of diagnosis and ascites before surgery had a statistically significant higher rate of recurrence. Similarly, patients with stage IV are more likely to relapse than those with stage III.…”

Factors Linked with Prognosis in Epithelial Ovarian Cancer: A Study From Lahore, Pakistan

“…In present research the p value for BMI when compared among normal and non-normal categories was 0.89 2 . While in another study which was carried out on 119 women of stage III and IV diagnosed with ovarian cancer, when BMI was compared it was non significant p 0.263 19,20 . Another study presented survival prognosis in early stage (90%) and 53.3% late stage 15,21 , which is in agreement with present study with 72% stage I, II vs 43% stage III, IV.…”